25e-NBOMe
25E-NBOMe is a synthetic psychedelic of the substituted phenethylamine class, derived from 2C-E through N-benzylation. It is a potent 5-HT2A receptor agonist that produces effects similar to related compounds such as 25I-NBOMe and 25C-NBOMe. Typically distributed on blotters, it has been sold as a research chemical and is sometimes misrepresented as LSD. Notable risks include significant vasoconstriction and heavy body load, with high doses posing potentially life-threatening cardiovascular effects.
Contents
Dosage & Duration
Dosage
Administered as blotter tabs or liquid held under the tongue. The NBOMe series exhibits highly variable individual sensitivity; conservative dosing from lower range is strongly recommended.
Duration
Subjective Effects
25E-NBOMe produces a strongly visual and stimulating psychedelic state typical of the NBOMe series, marked by euphoria, heightened empathy, and a broad alteration of perception. The headspace pairs insight and a softening of the ego with mental stimulation, though confusion can arise as intensity increases. The body load is distinctly stimulating rather than relaxing, with restlessness, muscle tension, and difficulty sleeping persisting through the experience.
Physical
The body load is stimulating and somewhat tense, with restlessness, muscle tension, sweating and chills, appetite loss, and pronounced wakefulness that can make sleep difficult until the effects subside.
Stimulation
The physical character of the experience is energetic and restless rather than relaxing.
Uncomfortable
Cognitive
The mental state combines euphoria, empathy, and introspective insight with a generally stimulated thought stream. Ego boundaries soften at higher intensities, and confusion is possible.
Emotional
Visual
Visual effects are a central component of the experience, appearing with both open and closed eyes and featuring markedly brightened color.
Tactile
Tactile sensation is enhanced, with touch feeling more pronounced and engaging.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
25E-NBOMe acts as an agonist at serotonin 5-HT2 receptors. In rodent models, the compound produces the head-twitch response, a behavioral proxy for psychedelic activity. 25E-NBOMe has also demonstrated reinforcing effects in rodents, including conditioned place preference and self-administration, which were mediated by increased dopaminergic signaling in the nucleus accumbens. Blockade of the dopamine D1 receptor was found to attenuate the conditioned place preference induced by the substance.
Pharmacokinetics
Tolerance
Harm Potential
Addiction & Dependence
Psychological
Rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration, mediated by increased dopaminergic signaling in the nucleus accumbens. Blockade of the dopamine D1 receptor attenuated these reinforcing effects.
Toxicity
Vasoconstriction is a noted effect that at high doses can potentially endanger life; users should exercise particular caution with dosing.
History & Culture
25E-NBOMe first appeared in scientific literature around 2012, emerging as part of the broader NBOMe series of substituted phenethylamines. This class of compounds, which includes related substances such as 25I-NBOMe and 25C-NBOMe, gained attention during this period as novel psychoactive substances. Following its initial scientific documentation, 25E-NBOMe subsequently appeared on the recreational drug market alongside other members of this chemical family.
Legality
By Country
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25e-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.